Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantheus Holdings
(NQ:
LNTH
)
90.27
+0.74 (+0.83%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantheus Holdings
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 08, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
February 06, 2023
MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
January 04, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Looking Into Lantheus Holdings's Return On Capital Employed
November 22, 2022
Via
Benzinga
Lantheus Holdings: Q3 Earnings Insights
November 03, 2022
Lantheus Holdings (NASDAQ:LNTH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
December 20, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Cramer's Take On This Stock Up 48% Year-To-Date: 'I Would Not Want To Come In At This Level'
December 15, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royal Caribbean Cruises Ltd (NYSE: RCL) is an "excellent" company.
Via
Benzinga
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
December 12, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
December 06, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
December 05, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 05, 2022
Via
Benzinga
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
December 05, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Holdings Stock Showing Market Leadership; Earns 94 RS Rating
November 29, 2022
Lantheus Holdings stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 90 to 94.
Via
Investor's Business Daily
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
November 29, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
November 28, 2022
DEFINITY is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
7 Index Funds to Buy to Retire a Millionaire
November 23, 2022
Although the market shows signs of improvement, the waters are still choppy enough for investors to focus on index funds to buy.
Via
InvestorPlace
3 Stocks That Could Be the Next Big M&A Targets
November 18, 2022
These three potential M&A deals run the gamut from very possible to very unlikely, despite the benefits of a transaction getting done.
Via
InvestorPlace
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
November 18, 2022
The good times could keep on rolling for these big winners.
Via
The Motley Fool
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
November 15, 2022
Via
Benzinga
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
November 14, 2022
Via
Benzinga
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
November 13, 2022
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Lantheus to Present at the Jefferies London Healthcare Conference
November 09, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Jim Cramer Says Tesla Has 'The Worst Chart I've Ever Seen': Is He Still A Believer?
November 08, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Antero Resources Corporation (NYSE: AR) is very, very cheap…and "I’m not going to say anything bad about it."
Via
Benzinga
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
November 04, 2022
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Lantheus Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
MarketBeat: Week in Review 10/24-10/28
October 29, 2022
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Economy
Electric Vehicles
Interest Rates
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
October 28, 2022
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.
Via
MarketBeat
Topics
ETFs
Initial Public Offering
Exposures
Securities Market
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
October 20, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.